BusinessSummit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDIBy Nasdaq OMXDec 21, 2017, 7:00 AM UTC
BusinessSummit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic RidinilazoleBy Nasdaq OMXNov 6, 2017, 2:29 PM UTC
BusinessSummit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017By Nasdaq OMXOct 9, 2017, 11:00 AM UTC
BusinessSummit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDIBy Nasdaq OMXSep 5, 2017, 11:01 AM UTC
BusinessPhase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile InfectionBy Nasdaq OMXApr 28, 2017, 10:30 PM UTC
BusinessSummit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational ProgressBy Nasdaq OMXDec 15, 2016, 12:00 PM UTC
BusinessSummit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 TrialBy Nasdaq OMXMar 7, 2016, 12:00 PM UTC
